Takeda has closed its deal to buy Dublin-based Shire Pharmaceuticals in a $62 billion takeover that means a big move into orphan drug development for the Osaka, Japan-based company. Many Big Pharma companies previously focused on mass-market indications like heart disease, high blood pressure and diabetes. But they've been moving away from that strategy, as a better understanding of genomics has made it possible (and more lucrative) to target drugs to very precise groups of patients. While Takeda has a portfolio of large-market drugs, as well as cancer therapies, roughly one-third of the products in its pipeline are designed to treat orphan diseases, making rare-disease specialist Shire a nice fit, said Andy Plump, Takeda’s chief medical and scientific officer. #jpm19 #LinkedInHealthcare
Congrats Andy
So amazing! Great leadership!
I couldn’t agree more in Mr. Plump view point on Data Analytics for clinical trials. But just do let me emphasized in having as a first foundation a secure track and trace system to link the trials of the new drugs with the patients and the evolution of the illness in time, by compiling events of information, after each dose. We can even use Blockchain to protect and preserve the collected data to later analyze the information that has been secured. I’ve been involved in several projects around the topic and I can assure that by combining the above mentioned IT solutions we can achieve reliable and accurate data to accelerate the time to market of new products and customize drugs per niche of patients.? #clinicaltrials?#dataanalytics?#blockchain?#trackandtrace?#medicines?#drugs?#pharma?#labs?#therapy
“The challenge that we're facing isn't the technology — the technology is there — it's changing standards of practice and ways of working it. It all comes down to culture.”
Good bye shire!
Congrats an d success
Happy to see Takeda making the switch from mass-market drug development to more focused forms of new drug discovery. It's an approach more drug companies need to take as this will have significant benefits for patients suffering from rare/genetic disease.
Well done Andy
SAP Controlling Architect
5 年Sanofi misses you Andy